[CH3:1][C:2]1[O:6][N:5]=[C:4]([C:7]2[N:11]3[NH:12][C:13](=[O:20])[C:14]4[C:19]([C:10]3=[N:9][CH:8]=2)=[CH:18][CH:17]=[CH:16][CH:15]=4)[CH:3]=1.[H-].[Na+].C(=O)([O-])[O-].[K+].[K+].Cl.Cl[CH2:31][C:32]1[N:33]=[N:34][N:35]([CH3:37])[CH:36]=1>CN(C=O)C.O>[CH3:1][C:2]1[O:6][N:5]=[C:4]([C:7]2[N:11]3[N:12]=[C:13]([O:20][CH2:31][C:32]4[N:33]=[N:34][N:35]([CH3:37])[CH:36]=4)[C:14]4[C:19]([C:10]3=[N:9][CH:8]=2)=[CH:18][CH:17]=[CH:16][CH:15]=4)[CH:3]=13-(5-Methylisoxazol-3-yl)imidazo[2,1-a]phthalazin-6-one (100 mg, 0.375 mmol) was suspended in DMF (5 ml) and sodium hydride (60% dispersion in oil, 33 mg, 0.83 mmol) was added. After stirring at room temperature for 10 minutes potassium carbonate (50 mg, 0.36 mmol) was added, followed by 4-chloromethyl-1-methyl triazole hydrochloride (69 mg, 0.41 mmol). The solution was heated at 80° C. for 4 hours, then cooled and poured into water. The solid product was filtered off and washed with water and hexane. The solid was recrystallised from ethyl acetate/hexane to yield the title compound (83 mg, 62%), 1H NMR (360 MHz, CDCl3) 2.55 (3H, s), 4.11 (3H, s), 5.75 (2H, s), 6.72 (1H, s), 7.67 (1H, t), 7.86 (1H, t), 7.99 (1H, s), 8.17 (2H, d), 8.51 (1H, d); MS+362 [MH]+.
読み込み中…
